Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation. Issue 1 (1st September 2020)

• Record Type: Journal Article
• Authors: Linder, Kathleen A.; Kauffman, Carol A.; Patel, Twisha S.; Fitzgerald, Linda J.; Richards, Blair J.; Miceli, Marisa H.
• Is Part Of: Transplant infectious disease. Volume 23:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-01
• Subjects: antifungal prophylaxis -- aspergillosis -- Candida infection -- invasive fungal infections -- lung transplant recipients; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.13448
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Background: Antifungal prophylaxis to prevent invasive fungal infections (IFI) is widely used following lung transplantation, but the optimal strategy remains unclear. We compared universal with targeted antifungal prophylaxis for effectiveness in preventing IFI. Methods: Adult patients who underwent lung transplantation at the University of Michigan from /1 July 2014‐31 December 2017 were studied for 18 months post‐transplant. Universal prophylaxis consisted of itraconazole with or without inhaled liposomal amphotericin B. Using specific criteria, targeted prophylaxis was given with voriconazole for patients at risk for invasive pulmonary aspergillosis (IPA) and with fluconazole or micafungin for patients at risk for invasive candidiasis. Risk factors, occurrence of proven/probable IFI, and mortality were analyzed for the two prophylaxis cohorts. Results: Of 105 lung transplant recipients, 84 (80%) received a double lung transplant, and 38 (36%) of patients underwent transplant for pulmonary fibrosis. Fifty‐nine (56%) patients received universal antifungal prophylaxis, and 46 (44%), targeted antifungal prophylaxis. Among 20 proven/probable IFI, there were 14 IPA, 4 invasive candidiasis, 1 cryptococcosis, and 1 deep sternal mold infection. Six (10%) IFI occurred in the universal prophylaxis cohort and 14 (30%) in the targeted prophylaxis cohort. Five of 6 (83%) IFI in the universal prophylaxis cohort, compared with 9/14 (64%) in the targeted prophylaxis cohort, were IPA Candida infections occurred only in the targeted prophylaxis cohort. The development of IFI was more likely in the targeted prophylaxis cohort than the universal prophylaxis cohort, HR = 4.32 (1.51‐12.38), P = .0064. Conclusions: Universal antifungal prophylaxis appears to be more effective than targeted antifungal prophylaxis for prevention of IFI after lung transplant.